NCT00626392 - Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia | Biotech Hunter

Enrollment

277

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Dyslipidemia

Interventions

DRUG

niacin extended-release (NER)

Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period

DRUG

aspirin (ASA)

325 mg tablets administered once daily

DRUG

aspirin placebo (ASA Pbo)

Tablets administered once daily

Trial Locations (26)

14609

Rochester

19047

Penndel

27103

Winston-Salem

28262

Charlotte

29464

Mt. Pleasant

29681

Simpsonville

32259

Jacksonville

33027

Pembroke Pines

33134

Coral Gables

33186

Miami

33407

West Palm Beach

35801

Huntsville

76034

Colleyville

77074

Houston

78229

San Antonio

85251

Scottsdale

85710

Tucson

85712

Tucson

90057

Los Angeles

Vista

91361

Westlake Village

92660

Newport Beach

92801

Anaheim

95204

Stockton

02747

North Dartmouth

02919

Johnston